Eleventx

ScionxBio, formerly Eleven Therapeutics, develops xRNA, an RNA molecule built on an expanded chemical alphabet with position-specific modifications. The company states these modifications extend protein expression from days to months. Its platform pairs synthetic chemistry with a deep-learning design engine called TERÅ, which runs a design, build, measure and learn cycle.

The company says it partners with pharmaceutical companies and investors to bring durable RNA medicines to chronic disease. Its first focus is cardiometabolic disease, with the same multi-pathway approach described as applicable to other chronic diseases driven by more than one cause. The website does not describe its revenue model.

ScionxBio is headquartered in Cambridge, UK, with offices in Tel Aviv, Israel, and Cambridge, Massachusetts, USA. Its CEO is Dr. Adi Gilboa-Geffen, and a news item dated July 1, 2026 reports the company's launch from Eleven Therapeutics. The website lists one open role, Analytical Chemist, based in Cambridge, UK.

Product: xRNA, an extended-release RNA platform with an expanded nucleotide alphabet, plus the TERÅ AI design engine for RNA therapeutics.